Recce Pharmaceuticals (ASX:RCE)

Executive Summary

Recce Pharmaceuticals (ASX:RCE) is an Australian clinical-stage biotech developing a novel class of synthetic polymer anti-infectives designed to overcome antibiotic resistance and address viral infections. Its lead candidate, RECCE 327, targets ESKAPE pathogens through a unique mechanism of action that evades resistance development. The company also has preclinical candidates for viral indications, broadening its pipeline. With Phase 3 trials underway and growing global concern over antimicrobial resistance, Recce is positioned to address a major unmet medical need. Recent progress includes advancing RECCE 327 into late-stage trials for serious bacterial infections, with potential for accelerated approval pathways. The company maintains a strong cash position and has attracted interest from global health organizations. Key upcoming catalysts include Phase 3 data readouts and potential regulatory submissions, which could drive significant value. However, risks remain typical of small-cap biotechs, including clinical and regulatory uncertainties.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 top-line data for RECCE 327 in complicated urinary tract infections55% success
• Q4 2026FDA fast track or breakthrough therapy designation for RECCE 32760% success
• H1 2027Announcement of licensing or partnership deal for RECCE 32740% success